Drugs / ALLO-501A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04416984 | May 2020 → Feb 2029 expected | B-cell non-Hodgkin lymphoma | Allogene Therapeutics | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05714345 Background | Nov 2023 → Feb 2024 | large B-cell lymphoma | Allogene Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALLO-501A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04416984 ↗ |
| Modality | Cell therapy | “ALLO-501A is an allogeneic CAR T cell therapy targeting CD19” NCT04416984 ↗ |
| Target | CD19 | “targeting CD19” NCT04416984 ↗ |